| Nov 17 |
Lipella Pharmaceuticals Third Quarter 2024 Earnings: US$1.29 loss per share (vs US$1.84 loss in 3Q 2023)
|
| Nov 12 |
Lipella Pharmaceuticals Secures Extended Market Exclusivity with Issuance of U.S. Patent for Liposomal Delivery Platform
|
| Nov 1 |
Lipella Pharmaceuticals announces 1-for-8 reverse stock split
|
| Nov 1 |
Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split
|
| Oct 15 |
Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform
|
| Oct 9 |
Lipella Pharmaceuticals to Present at 2024 Maxim Healthcare Virtual Summit
|
| Sep 25 |
PRISM MarketView Features Q&A with Dr. Michael Chancellor: Lipella Pharmaceuticals Advances Innovative Treatments for Hemorrhagic Cystitis During Urology Awareness Month
|
| Aug 27 |
Lipella Pharmaceuticals to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York
|
| Aug 16 |
Lipella Pharmaceuticals Second Quarter 2024 Earnings: US$0.12 loss per share (vs US$0.27 loss in 2Q 2023)
|
| Aug 1 |
Lipella Pharmaceuticals Announces Closing of $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules
|
